Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Claus Steppert (Bayreuth, Germany), Claus Steppert, Hannah Foerster, Rumo Leistner, Jens Krugmann. TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis. Eur Respir J 2015; 46: Suppl. 59, 4292

Member's Comments

No comment yet.

Related content which might interest you: Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Concurrent chemoradiation in stage III NSCLC: High eligilbility and high rates of overall and progression-free survival with acceptable toxicity Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Long-term survival is linked to serum LDH normalization in SCLC Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Survival in 138 patients with non small cell lung cancer (NSCLC) treated with platinum together with gemcitabine or vinorelbine by a multidisciplinary team. Comparison with the Big Lung Trial Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The role of second line chemotherapy in small cell lung cancer: A retrospective analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014